Bromocriptine - Revision history

Danbot: Switch SMW query from broadtable to table format for better layout with TOC

2026-03-20T21:57:50Z

Switch SMW query from broadtable to table format for better layout with TOC

← Older revision		Revision as of 21:57, 20 March 2026
Line 106:		Line 106:
	\|?Has Route=Route		\|?Has Route=Route
	\|?Has Population=Population		\|?Has Population=Population
	\|format=~~broadtable~~		\|format=table
	\|headers=plain		\|headers=plain
	\|mainlabel=-		\|mainlabel=-

Danbot: Fix SMW query: replace link=subject with mainlabel=- to fix broken subobject fragment links

2026-03-20T17:25:31Z

Fix SMW query: replace link=subject with mainlabel=- to fix broken subobject fragment links

← Older revision		Revision as of 17:25, 20 March 2026
Line 108:		Line 108:
	\|format=broadtable		\|format=broadtable
	\|headers=plain		\|headers=plain
	\|~~link~~=~~subject~~		\|mainlabel=-
	\|sort=Has Indication		\|sort=Has Indication
	\|limit=50		\|limit=50

Danbot: Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)

2026-03-20T16:43:33Z

Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)

← Older revision		Revision as of 16:43, 20 March 2026
Line 95:		Line 95:

	==Comments==		==Comments==


			==Indications by Condition==
			''The following table is automatically generated from disease/condition pages across WikEM.''

			{{#ask:[[Has DrugName::Bromocriptine]]
			\|?Has Indication=Indication
			\|?Has Dose=Dose
			\|?Has Context=Context
			\|?Has Route=Route
			\|?Has Population=Population
			\|format=broadtable
			\|headers=plain
			\|link=subject
			\|sort=Has Indication
			\|limit=50
			}}

	==See Also==		==See Also==

ClaireLewis at 21:36, 19 September 2019

2019-09-19T21:36:59Z

← Older revision		Revision as of 21:36, 19 September 2019
Line 102:		Line 102:
	<references/>		<references/>
	[[Category:Pharmacology]]		[[Category:Pharmacology]]
			[[Category:Toxicology]]

Humanguy: edited dosage forms, strengths, routes of administration

2017-10-11T23:09:46Z

edited dosage forms, strengths, routes of administration

← Older revision		Revision as of 23:09, 11 October 2017
Line 1:		Line 1:
	==Administration==		==Administration==
	*Type: Dopamine agonist		*Type: Dopamine agonist
	*Dosage Forms: 2.~~5, 5 mg~~		*Dosage Forms: capsule, tablet
	*Routes of Administration: ~~Oral~~		*Dosage Strengths: capsule: 5mg; tablet: 0.8, 2.5mg
			*Routes of Administration: PO
	*Common Trade Names: Parlodel, Cycloset		*Common Trade Names: Parlodel, Cycloset

Mholtz: Text replacement - "qd" to "QD"

2017-07-07T12:42:10Z

Text replacement - "qd" to "QD"

← Older revision		Revision as of 12:42, 7 July 2017
Line 7:		Line 7:
	==Adult Dosing==		==Adult Dosing==
	*Acromegaly		*Acromegaly
	**20-30 mg PO qd		**20-30 mg PO QD
	***Start: 1.25-2.5 mg PO qhs x3 days		***Start: 1.25-2.5 mg PO qhs x3 days
	****Increase by 1.25-2.5 mg per day q 3-7 days		****Increase by 1.25-2.5 mg per day q 3-7 days
Line 13:		Line 13:
	***Give with food and taper dose to D/C		***Give with food and taper dose to D/C
	*Hyperprolactinemia		*Hyperprolactinemia
	**2.5-15 mg PO qd		**2.5-15 mg PO QD
	***Start: 1.5-2.5 mg PO qd		***Start: 1.5-2.5 mg PO QD
	****Increase by 1.25-2.5 mg per day q 2-7 days		****Increase by 1.25-2.5 mg per day q 2-7 days
	***Give with food and taper dose to D/C		***Give with food and taper dose to D/C
Line 31:		Line 31:
	*Adenoma, prolactin-secreting		*Adenoma, prolactin-secreting
	**11-15 yo		**11-15 yo
	***2.5-10 mg PO qd		***2.5-10 mg PO QD
	****Start: 1.25-2.5 mg PO qd		****Start: 1.25-2.5 mg PO QD
	****Give with food and taper dose to D/C		****Give with food and taper dose to D/C
	**16+ yo		**16+ yo
	***2.5-15 mg PO qd		***2.5-15 mg PO QD
	****Start: 1.25-2.5 mg PO qd		****Start: 1.25-2.5 mg PO QD
	****Give with food and taper dose to D/C		****Give with food and taper dose to D/C

Mholtz: Text replacement - "qid" to "QID"

2017-07-07T07:14:55Z

Text replacement - "qid" to "QID"

← Older revision		Revision as of 07:14, 7 July 2017
Line 22:		Line 22:
	***Give with food and taper dose to D/C		***Give with food and taper dose to D/C
	*[[Neuroleptic malignant syndrome]]		*[[Neuroleptic malignant syndrome]]
	**5-10 mg PO tid-~~qid~~		**5-10 mg PO tid-QID
	***Start: 2.5 mg PO tid-~~qid~~		***Start: 2.5 mg PO tid-QID
	****Increase dose as tolerated		****Increase dose as tolerated
	***Max: 20 mg PO ~~qid~~		***Max: 20 mg PO QID
	***Continue x7-10 days, then taper dose over 3 days to D/C		***Continue x7-10 days, then taper dose over 3 days to D/C

ClaireLewis at 02:06, 11 December 2016

2016-12-11T02:06:40Z

← Older revision		Revision as of 02:06, 11 December 2016
Line 62:		Line 62:
	*[[Seizure]]		*[[Seizure]]
	*[[Stroke]]		*[[Stroke]]
	*~~Hallucination~~		*[[Hallucinations]]
	*[[Syncope]]		*[[Syncope]]
	*[[Hypotension]], ~~severe~~		*[[Hypotension]]
	*[[MI]]		*[[Arrhythmia]], [[MI]]
	*[[~~Arrhythmia~~]]		*[[Pericardial effusion]], constrictive [[pericarditis]]
			*[[Pleural effusion]], [[pulmonary fibrosis]]
	*[[Hypertension]]		*[[Hypertension]]
	*Raynaud phenomenon		*Raynaud phenomenon
	*[[Pleural effusion]]
	*[[Pericardial effusion]]
	*[[Pulmonary fibrosis]]
	*Retroperitoneal fibrosis		*Retroperitoneal fibrosis
	*Constrictive pericarditis
	*[[GI bleeding]]		*[[GI bleeding]]
	*~~NMS~~-like symptoms if abrupt ~~D/C~~		*[[Neuroleptic malignant syndrome]]-like symptoms if abrupt discontinuation

	===Common===		===Common===
	*[[Nausea]]		*[[Nausea/vomiting]], [[diarrhea]], [[constipation]], [[dyspepsia]], anorexia, [[abdominal pain]]
	*[[Headache]]		*[[Headache]], [[dizziness]], [[fatigue]]
	*[[~~Dizziness~~]]
	*Drowsiness
	*[[~~Fatigue~~]]
	*Lightheadedness
	*Nasal congestion		*Nasal congestion
	*[[~~Abdominal pain]]~~		*Orthostatic [[hypotension]], orthostatic
	*[[Diarrhea]]		*Involuntary movements, [[ataxia]], visual disturbances
	*[[Constipation]]		*Compulsive behaviors
	*[[Hypotension]], orthostatic
	*~~Anorexia~~
	*[[~~Dyspepsia~~]]
	*~~Involuntary movments~~
	*Visual disturbance
	*Digital vasospasm		*Digital vasospasm
	*[[Vomiting]]		*ALT, AST, alk phos elevation
	*[[Ataxia]]
	*ALT, AST elevation
	*Alk Phos elevation
	*Compulsive behaviors

	==Pharmacology==		==Pharmacology==

Jonwarren: Creation of page

2016-12-01T03:15:21Z

Creation of page

New page

==Administration==
*Type: Dopamine agonist
*Dosage Forms: 2.5, 5 mg
*Routes of Administration: Oral
*Common Trade Names: Parlodel, Cycloset

==Adult Dosing==
*Acromegaly
**20-30 mg PO qd
***Start: 1.25-2.5 mg PO qhs x3 days
****Increase by 1.25-2.5 mg per day q 3-7 days
***Max: 100 mg per day
***Give with food and taper dose to D/C
*Hyperprolactinemia
**2.5-15 mg PO qd
***Start: 1.5-2.5 mg PO qd
****Increase by 1.25-2.5 mg per day q 2-7 days
***Give with food and taper dose to D/C
*[[Parkinson's disease]]
**10-30 mg PO tid
***Max: 100 mg/day
***Give with food and taper dose to D/C
*[[Neuroleptic malignant syndrome]]
**5-10 mg PO tid-qid
***Start: 2.5 mg PO tid-qid
****Increase dose as tolerated
***Max: 20 mg PO qid
***Continue x7-10 days, then taper dose over 3 days to D/C

==Pediatric Dosing==
*Adenoma, prolactin-secreting
**11-15 yo
***2.5-10 mg PO qd
****Start: 1.25-2.5 mg PO qd
****Give with food and taper dose to D/C
**16+ yo
***2.5-15 mg PO qd
****Start: 1.25-2.5 mg PO qd
****Give with food and taper dose to D/C

==Special Populations==
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B; No known risk of fetal harm based on human data. Monitor hyperprolactinemic pts closely for potential prolactin-secreting tumor enlargement.
*[[Lactation risk categories|Lactation risk]]: L5; Contraindicated in postpartum lactation

===Renal Dosing===
*Adult: Not defined. Caution advised.
*Pediatric: Not defined. Caution advised.

===Hepatic Dosing===
*Adult: Not defined. Caution advised.
*Pediatric: Not defined. Caution advised.

==Contraindications==
*Allergy to class/drug
*Hypersensitivity to ergot derivatives
*[[Hypertension]], uncontrolled
*Breastfeeding
*Avoid abrupt withdrawal

==Adverse Reactions==
===Serious===
*[[Seizure]]
*[[Stroke]]
*Hallucination
*[[Syncope]]
*[[Hypotension]], severe
*[[MI]]
*[[Arrhythmia]]
*[[Hypertension]]
*Raynaud phenomenon
*[[Pleural effusion]]
*[[Pericardial effusion]]
*[[Pulmonary fibrosis]]
*Retroperitoneal fibrosis
*Constrictive pericarditis
*[[GI bleeding]]
*NMS-like symptoms if abrupt D/C

===Common===
*[[Nausea]]
*[[Headache]]
*[[Dizziness]]
*Drowsiness
*[[Fatigue]]
*Lightheadedness
*Nasal congestion
*[[Abdominal pain]]
*[[Diarrhea]]
*[[Constipation]]
*[[Hypotension]], orthostatic
*Anorexia
*[[Dyspepsia]]
*Involuntary movments
*Visual disturbance
*Digital vasospasm
*[[Vomiting]]
*[[Ataxia]]
*ALT, AST elevation
*Alk Phos elevation
*Compulsive behaviors

==Pharmacology==
*Half-life: Biphasic 4-4.5 hr and 15 hr
*Metabolism: Liver; CYP450: 3A4 substrate
*Excretion: Bile 95%, urine 2.5-5.5%

==Mechanism of Action==
*Stimulates dopamine receptors
*Inhibits anterior pituitary prolactin secretion

==Comments==

==See Also==
*[[Neuroleptic malignant syndrome]]

==References==
<references/>
[[Category:Pharmacology]]